OBJECTIVE
To evaluate the efficacy of alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis through clinical case examples from routine medical practice.
MATERIAL AND METHODS
Four clinical cases were selected to demonstrate the effectiveness of alpha-glutamyl-tryptophan as an anti-inflammatory agent and promoter of gastric mucosal repair in patients with chronic atrophic gastritis of varying etiologies (Helicobacter pylori-associated and autoimmune). Alpha-glutamyl-tryptophan was administered for 28 days. In cases of H. pylori-associated gastritis, it was used following standard eradication therapy, whereas in H. pylori-negative autoimmune gastritis, it was used as a first-line treatment.
RESULTS
Patients with gastric mucosal atrophy who received alpha-glutamyl-tryptophan exhibited clinical improvement (symptom resolution post-treatment), histological improvement (reduced inflammation and atrophy regression, indicated by increased gland density per mm² of gastric mucosa), and improved gastric function (elevation in pepsinogen I levels). The most challenging case involved H. pylori-associated atrophic gastritis in a patient with uncontrolled nonsteroidal anti-inflammatory drug use; nonetheless, alpha-glutamyl-tryptophan as part of a comprehensive treatment demonstrated regenerative and anti-inflammatory effects.
CONCLUSION
The presented clinical cases suggest that alpha-glutamyl-tryptophan (Regastim Gastro) contributes to the regression of atrophy, improvement of functional activity, and reduction of inflammation in the gastric mucosa. For chronic atrophic gastritis, particularly in autoimmune cases, repeated courses of treatment are recommended with intervals of at least two weeks.